This week, ZenPharm, the Maltese joint venture with Canadian cannabis producer, Zenabis Global, received its Maltese licence to process cannabis for medicinal use and research purposes out of its Hal Far Industrial Estate premises.
Kurt Farrugia, CEO of Malta Enterprise – the national economic development agency that assisted the company to set up locally – considers this “an important milestone for Malta’s medical cannabis industry.”
“We are gaining momentum with the production of cannabis for medical use in Malta,” he wrote. “Zenabis – a Maltese joint venture and partner of Zenpharm, have received a licence for the production of medical cannabis in their facility in Hal Far, Malta.”
The CEO said that the issuing of the second licence for the production of cannabis for medical use shows that “Malta is becoming a centre of excellence in such an important emerging sector.”
“Those companies strive hard to achieve the Medicine's Authority pharmaceutical standards. Now that they do, patients can rest assured that the Made in Malta product is top quality. A gold standard for the industry. This is indeed a proud moment.”
Through its licence, ZenPharm plans to ship around 500kg of cannabis out of Malta annually to EU countries, with the largest market being Germany.
Featured Image:
Kurt Farrugia / LinkedIn
Moving beyond the insurance policy – How Veracloud is rethinking cybersecurity
Veracloud’s Clint Deguara and John Ellul explain why businesses need to embrace specialist partnerships, proactive protection and a secure-by-design approach
EC President proposes Canada as associate EU member, under-13 social media ban
'I would like to work with you on opening the door for Canada to be the first associate member of ...
‘Our companies have complementary strengths’ – Melita CEO on Epic acquisition
Melita has announced that it is acquiring a 100% stake in Epic.
Ivan Isola launches Riesgo Advisory Limited and takes on Director role
Ivan Isola is a certified public accountant and has been financial consulting for over ten years.
